Therapeutic Class
mRNA will be part of a solid landscape in 2023, says Cytiva
Therapeutic ClassmRNA will be part of a solid landscape in 2023, says CytivamRNA will be part of a solid landscape in 2023, says Cytiva
Ligner, CEO of Cytiva, predicts mRNA will become a well proven modality with continued investment in clinical pipelines going beyond COVID.